Rescinnamine (Rauvolfia Indole Alkaloid · Antihypertensive · Informational)

Compound	Rescinnamine
Chemical class	Alkaloid — Indole (yohimbane-type; Rauvolfia alkaloid; reserpine analogue)
CAS	24815-24-5
Primary source	Rauvolfia serpentina (Indian snakeroot, Sarpagandha), roots
Key applications	Historic antihypertensive; reserpine-related Rauwolfia alkaloid; informational-only
Claim strength	High (pharmaceutical, historic)
Typical form	Pharmaceutical (historic); not a supplement ingredient
Buy from Herbuno	Informational reference — see HerbIQ Compound Index →

Name origin: Rescinnamine is the trimethoxycinnamoyl ester analogue of reserpine, its name marking both the reser-/Rauwolfia lineage and the cinnamate ester that distinguishes it from reserpine’s benzoate. It is a yohimbane-type Rauwolfia indole alkaloid, one of the three principal alkaloids — with reserpine and deserpidine — that defined the therapeutic profile of the genus. Traditional use: As a constituent of Rauvolfia serpentina (Sarpagandha), rescinnamine belongs to the alkaloid complex behind the plant’s long Ayurvedic and Unani use for hypertension, agitation, insomnia, and febrile delirium. It has no distinct traditional identity of its own, arising instead as one component of the whole-root preparation. Research trajectory: Rescinnamine was isolated in the 1950s as a second sedative and antihypertensive Rauwolfia alkaloid and became an active component of standardised extracts such as alseroxylon, which combined reserpine and rescinnamine and produced consistent blood-pressure reductions in early outpatient studies of hypertensive patients Lobay 2015. Analytical methods were subsequently developed to resolve and quantify reserpine and rescinnamine together in Rauwolfia powders and tablets analysis 1987. Commercial source: Rescinnamine is a historic pharmaceutical alkaloid, included in HerbIQ as a chemical-family reference.

---

Evidence for Rescinnamine Applications

Antihypertensive use: Rescinnamine, alongside reserpine, was an active constituent of the standardised Rauwolfia extract alseroxylon, which produced consistent reductions in blood pressure of more than 20 mmHg in early outpatient studies of hypertensive patients Lobay 2015. This places it among the botanical-derived antihypertensives that helped establish the field. Claim strength: High (pharmaceutical, historic).

Rauwolfia alkaloid chemistry: Rescinnamine co-occurs with reserpine and deserpidine in Rauwolfia roots and can be resolved and quantified analytically alongside reserpine, for example by liquid chromatography with fluorescence detection using distinct excitation and emission wavelengths for the two esters analysis 1987. This analytical separability is important because the alkaloids share so much of their structure. Claim strength: High.

Reserpine relationship: As a close structural analogue of reserpine differing only in its ester side chain, rescinnamine shares the vesicular-monoamine-depleting pharmacology characteristic of the class, acting through inhibition of vesicular monoamine transport to deplete noradrenaline, dopamine, and serotonin stores. Claim strength: Moderate.

Historic significance: Rescinnamine is part of the mid-twentieth-century Rauwolfia antihypertensive story that helped establish botanical-derived cardiovascular pharmacology and that, through reserpine, contributed to the early monoamine hypothesis of mood disorders. Claim strength: Moderate.

Distribution in the plant: Rescinnamine is concentrated, like the other Rauwolfia alkaloids, in the root and root bark, and its content varies with plant source and part, which is why standardised extracts and analytical assay were historically necessary to deliver a consistent dose. Claim strength: Moderate.

Mechanistic class membership: As a reserpine analogue, rescinnamine acts through the same vesicular-monoamine-transport inhibition that defines the class, depleting stored noradrenaline, dopamine, and serotonin; its slightly different ester side chain modifies its pharmacokinetics rather than its fundamental mechanism, which is why it was therapeutically interchangeable with reserpine in the standardised extracts of the period. Claim strength: Moderate.

---

Dosage & Formulator Specification

Rescinnamine is a historic pharmaceutical alkaloid with no dietary-supplement application and no consumer dosing. Rauwolfia antihypertensives were dosed in fraction-of-a-milligram amounts under medical supervision, reflecting the potency and side-effect profile of the class.

Rauvolfia serpentina is a regulated botanical, and isolated Rauwolfia alkaloids carry defined cardiovascular and CNS risks, including the depression and sedation associated with central monoamine depletion. There is no supplement-grade rescinnamine application, and formulators should treat any Rauvolfia material as a controlled multi-alkaloid feedstock rather than an ingredient.

Where Rauvolfia material is handled at all, analytical control is essential: reserpine and rescinnamine can be resolved and quantified together by liquid chromatography with fluorescence detection, and total-alkaloid profiling by HPLC is the appropriate specification. The natural variation in alkaloid content between plants and plant parts makes batch-level assay, rather than assumed composition, the only defensible basis for handling, exactly as it was for the standardised extracts of the 1950s.

The historical arc of rescinnamine is instructive for how botanical pharmacology matured. It was delivered first as part of a crude standardised extract (alseroxylon), then as a purified single alkaloid once analytical separation of the closely related Rauwolfia esters became routine, and finally set aside as better-tolerated synthetic antihypertensives arrived. That progression — crude extract to purified alkaloid to obsolescence — is a recurring pattern for potent botanical alkaloids and is part of why HerbIQ documents the Rauvolfia group in such detail as a chemical-family reference.

This page documents rescinnamine as a chemical-family reference within the HerbIQ index, connecting it to reserpine, deserpidine, ajmaline, and the other Rauvolfia alkaloids documented elsewhere, and is explicitly not a sourcing recommendation.

---

Frequently Asked Questions — Rescinnamine

What is rescinnamine?
Rescinnamine is a yohimbane-type indole alkaloid of Rauvolfia serpentina, closely related to reserpine, that was used historically as an antihypertensive. It is the trimethoxycinnamoyl ester analogue of reserpine and was a component of standardised Rauwolfia extracts such as alseroxylon.

How does rescinnamine differ from reserpine?
Rescinnamine differs from reserpine in its ester side chain (a trimethoxycinnamoyl group in place of reserpine’s trimethoxybenzoyl), while sharing the same Rauwolfia origin, the same yohimbane skeleton, and the same vesicular-monoamine-depleting pharmacology. The two co-occur in Rauwolfia roots and were often delivered together in early standardised extracts.

Why is rescinnamine informational-only?
It is a prescription-era antihypertensive alkaloid, not a dietary-supplement ingredient, and appears in HerbIQ as a chemical-family reference to the Rauvolfia alkaloids rather than as a sourceable ingredient.

Is rescinnamine still used?
Like other Rauvolfia alkaloids, rescinnamine has largely been superseded by modern antihypertensives, and it is now of pharmacological and historical interest rather than routine clinical use. It remains relevant as a marker compound in the analysis of Rauwolfia material.

Related compounds: Reserpine, Deserpidine, Ajmaline, Serpentine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery